Rouvas A A, Ladas I D, Papakostas T D, Moschos M M, Vergados I
2nd Department of Ophthalmology, Medical School of Athens University, Athens, Greece.
Eur J Ophthalmol. 2007 Nov-Dec;17(6):996-9. doi: 10.1177/112067210701700623.
To report the effect of a single intravitreal injection of ranibizumab in a patient with choroidal neovascularization (CNV) secondary to multiple evanescent white dot syndrome (MEWDS).
A 65-year-old woman with visual acuity (VA) 20/40, mild vitreous inflammation, optic disc edema, and white deep retinal round lesions in the right eye underwent fluorescein angiography, indocyanine green angiography, and optical coherence tomography. The diagnosis of MEWDS with peripapillary CNV was made and a single injection of ranibizumab (0.5 mg) was administered.
At the 6-month follow-up visit, the VA in the right eye was 20/20, the CNV completely regressed, and the MEWDS findings disappeared.
Intravitreal ranibizumab appears to be a safe and effective treatment option in cases of CNV secondary to MEWDS, resulting in fast resolution of the macular edema and regression of the CNV. On the other hand, it is unclear whether the administration of ranibizumab contributed to a prompt regression of MEWDS.
报告玻璃体内单次注射雷珠单抗对一名继发于多发性一过性白点综合征(MEWDS)的脉络膜新生血管(CNV)患者的疗效。
一名65岁女性,右眼视力(VA)为20/40,有轻度玻璃体炎症、视盘水肿和视网膜深层白色圆形病灶,接受了荧光素血管造影、吲哚菁绿血管造影和光学相干断层扫描。诊断为伴有视乳头周围CNV的MEWDS,并单次注射雷珠单抗(0.5毫克)。
在6个月的随访中,右眼视力为20/20,CNV完全消退,MEWDS表现消失。
玻璃体内注射雷珠单抗似乎是治疗继发于MEWDS的CNV的一种安全有效的选择,可快速消退黄斑水肿并使CNV消退。另一方面,尚不清楚雷珠单抗的使用是否有助于MEWDS的迅速消退。